26 November 2024
LONDONMETRIC PROPERTY PLC (“LondonMetric” or the “Group” or the “Company”) HALF YEAR RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024 Cementing our position…
CRANSWICK plc: INTERIM RESULTS Strong volume-led earnings growth 26 November 2024 Cranswick plc (“Cranswick” or “the Company” or “the Group”), a leading UK food…
Publication of Circular and Notice of General Meeting Caledonia Investments plc (“Caledonia” or “the Company“) announces a proposal to refresh the Company’s existing authority…
Caledonia Investments plc Half-year results for the six months ended 30 September 2024 Financial highlights Six months ended 30th Sept 2024 Year ended…
25 November 2024
Financial Summary As at 30th September 2024 NAV per share 388.5p Total Assets £466.2m Ordinary shares Share price 227.0p Discount 41.6% Gross Yield 1.4%…
Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial First and only…
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma · Regulatory submission supported by phase III head-to-head DREAMM-7 and…
22 November 2024
FW Thorpe Plc Annual General Meeting statement At the Annual General Meeting of FW Thorpe Plc, held at 3.15pm 21 November 2024, Chairman, Mike…